Novartis goes 0 for 2 in PD-1 blockade
BeiGene regains rights to tislelizumab as another oncology asset blows up for Novartis.
Bristol seeks novelty in TIGIT
Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.
AbbVie opt-out puts the focus on TeneoOne
The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.
World Lung 2023 – targeted therapy to the rescue in small-cell lung
Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.
Exelixis claims a label-expanding Cabo success at last
However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.
A subcutaneous answer to PD-1’s patent problem
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
World Lung 2023 preview – Astra’s Tagrisso showdown
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
A short-lived hold for Arcellx & Gilead
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.
Astra goes pivotal with CTLA-4
Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.
